BioPharma Resources

Drug Trial Radar · NCT04684108

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

A Phase 1 Study of SG301 in Subjects With Hematological Malignancies

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

61

Actual

Start

Nov 4, 2021

Primary completion

Jun 30, 2024

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Conditions

  • Relapsed or Refractory Multiple Myeloma
  • Hematological Malignancy

Interventions

  • SG301Drug

    Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: Through study completion, an average of one year
  2. MTD/MAD/ RP2DTime frame: Through study completion, an average of one year

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Affiliated Beijing Chaoyang Hospital of Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Jishuitan Hostipal

    Beijing, Beijing Municipality, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangzhou, China

  • The Fourth Affiliated Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Wuhan University Central South Hospital

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • Wuxi Central Hospital

    Wuxi, Jiangsu, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Shanxi Norman Bethune Hospital

    Taiyuan, Shanxi, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.